제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
The Effect of Long-term Sodium-glucose Cotransporter 2 Inhibitor Treatment on Renal Function in the Patients with Type 2 Diabetes
백종하, 오태정, 문주영, 김태희, 고승현, 문민경, 김현정, 이동원, 허규연,
소속 상세정보
백종하 ( Baek Jong-Ha )
Gyeongsang National University School of Medicine Gyeongsang National University Changwon Hospital Department of Internal Medicine
오태정 ( Oh Tae-Jung )
Seoul National University College of Medicine Seoul National University Bundang Hospital Department of Internal Medicine
문주영 ( Moon Ju-Young )
Kyung Hee University School of Medicine Kyung Hee University Hospital at Gangdong Department of Internal Medicine
김태희 ( Kim Tae-Hee )
Inje University Busan Paik Hospital Department of Internal Medicine
고승현 ( Ko Seung-Hyun )
Catholic University College of Medicine St. Vincent’s Hospital Department of Internal Medicine
문민경 ( Moon Min-Kyong )
Seoul National University College of Medicine Boramae Medical Center Department of Internal Medicine
김현정 ( Kim Hyun-Jung )
Korea University College of Medicine Department of Preventive Medicine
이동원 ( Lee Dong-Won )
Pusan National University Yangsan Hospital Department of Internal Medicine
허규연 ( Hur Kyu-Yeon )
Sungkyunkwan University School of Medicine Samsung Medical Center Department of Medicine
Abstract
Chronic kidney disease is developed commonly in type 2 diabetes mellitus (T2DM) and is the most common cause of end-stage renal disease and related cardiovascular complications. Meanwhile, despite the current standard of care including optimized glucose control and the use of single-agent blockade of the renin-angiotensin-aldosterone system (RAAS), patients with T2DM remain at increased risk for death and complications from cardiorenal causes. The recent studies using sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown not only glucose lowering effect, but also a reduction in blood pressure, weight loss, and a lowering cardiovascular risk. Regarding renal outcomes, the use of SGLT2 inhibitor slows the progression of kidney disease compared to placebo when added to standard care. However, concern has been raised that currently available SGLT2 inhibitors in Korea may be also associated with improved renal outcomes with long-term treatment. As a result, we aimed to evaluate the effect of long-term SGLT2 inhibitor treatment on renal function in the patients with T2DM using meta-analysis.
키워드
Chronic kidney disease; Diabetes mellitus, type 2; Sodium-glucose cotransporter 2 inhibitor; Meta-analysis
원문 및 링크아웃 정보
등재저널 정보